콘텐츠로 건너뛰기
Merck
모든 사진(1)

Key Documents

53571-U

Supelco

Ascentis® Express 90 Å F5 (2.7 μm) HPLC Columns

L × I.D. 15 cm × 2.1 mm, HPLC Column

동의어(들):

Core-shell (SPP) Fused Core PFP HPLC column

로그인조직 및 계약 가격 보기


About This Item

UNSPSC 코드:
41115700
eCl@ss:
32110501
NACRES:
SB.52

product name

Ascentis® Express F5, 2.7 μm HPLC Column, 2.7 μm particle size, L × I.D. 15 cm × 2.1 mm

material

stainless steel column

Quality Level

Agency

suitable for USP L43

제품 라인

Ascentis®

특징

endcapped

제조업체/상표

Ascentis®

포장

1 ea of

파라미터

60 °C temp. range
600 bar max. pressure (9000 psi)

기술

HPLC: suitable
LC/MS: suitable
UHPLC-MS: suitable
UHPLC: suitable

길이 × I.D.

15 cm × 2.1 mm

표면적

135 m2/g

불순물

<5 ppm metals

기질

Fused-Core particle platform
superficially porous particle

기질 활성군

PFP (pentafluorophenyl) phase

입자 크기

2.7 μm

공극 크기

90 Å pore size

작동 pH

2-8

응용 분야

food and beverages

분리 기술

reversed phase

유사한 제품을 찾으십니까? 방문 제품 비교 안내

일반 설명

The pentafluorophenylpropyl stationary phase of Ascentis Express F5 provides a stable reversed phase packing with electron-deficient phenyl rings due to the presence of electronegative fluorines.In addition to forming pi-pi and mildly steric interactions, F5 phases also retain compounds by polar interactions. Ascentis Express F5 can be used for basic, acidic, or neutral compounds with alternate selectivity from C18.

애플리케이션

  • Liquid chromatographic determination of lumacaftor in the presence of ivacaftor and identification of five novel degradation products using high-performance liquid chromatography ion trap time-of-flight mass spectrometry.: This study employs the Ascentis® Express F5, 2.7 μm HPLC Column to enhance the resolution and sensitivity in the analysis of lumacaftor and ivacaftor, critical medications for treating cystic fibrosis. The method provides significant insights into the stability and degradation pathways of these drugs, facilitating improved drug formulation and storage conditions (Ozcan et al., 2023).
  • Stability-indicating LC-MS/MS and LC-DAD methods for robust determination of tasimelteon and high resolution mass spectrometric identification of a novel degradation product.: Utilizing the Ascentis® Express F5, 2.7 μm HPLC Column, this research develops advanced analytical techniques for tasimelteon, a treatment for non-24-hour sleep-wake disorder. The methods ensure accurate quantification and stability assessment, crucial for clinical efficacy and patient safety (Ozcan et al., 2020).

법적 정보

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Iltaf Shah et al.
The Journal of steroid biochemistry and molecular biology, 180, 118-128 (2018-02-13)
Research shows that immunoassay techniques are not the best choice for the estimation of vitamin D in human blood samples. The main reasons are that some immunoassays are not able to distinguish between 25-OHD3 and 25-OHD2 vitamin D metabolites. Furthermore

문서

Novel sample prep technique coupled with the unique selectivity of the Ascentis Express F5 column enables a fast and simplified bioanalytical method for associated vitamin D metabolites.

Using HybridSPE-Phospholipid, Ascentis Express, and Other LC-MS Workflow Components

Enhanced selectivity for stereoisomers and closely related compounds with alternate selectivity from C18 phases for basic, acidic, or neutral compounds

프로토콜

Fast and Accurate LC-MS Analysis of Vitamin D Metabolites, Using Ascentis® Express F5 HPLC Columns from Supelco®

Chromatograms

application for HPLCapplication for HPLC

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.